



CCM DUOPHARMA BIOTECH BERHAD

(Company No: 524271-W)

(Incorporated in Malaysia)

**ERRATA
TO
ANNUAL REPORT 2015**

Errata

Material Contracts

In respect of Material Contracts disclosure under Additional Compliance Information on Page 71 of the 2015 Annual Report, save for the following, there were no material contracts entered into by the CCMD Group during the two (2) years preceding the date of this Circular, other than contracts entered into in the ordinary course of business:-

- (i) A conditional share sale agreement dated 27 November 2014 for the proposed acquisition of the entire equity interest in CCM Pharmaceuticals Sdn Bhd (“CCM Pharmaceuticals”) and Innovax Sdn Bhd (“Innovax”) by CCM Duopharma Biotech Berhad from Chemical Company of Malaysia Berhad (“CCMB”) for an aggregate purchase consideration of RM17,600,000 together with the settlement of advances due from Innovax, and CCM Pharmaceuticals and its subsidiaries to CCMB and its subsidiaries (“CCMB Group”) amounting to RM10,655,000 based on 30 September 2014 to be settled via cash (“CCMD SSA”);
- (ii) A conditional share sale agreement dated 27 November 2014 for the proposed acquisition of the entire equity interest in CCM International (Philippines), Inc (“CCM Philippines”) by CCM Duopharma Biotech Berhad from CCM Investments Ltd, a wholly-owned subsidiary of CCMB (“CCM Investments”) for a purchase consideration of RM1,000 to be settled via cash (“Philippines Company SSA”);
- (iii) A conditional share sale agreement dated 27 November 2014 for the proposed acquisition of the entire equity interest in CCM Pharmaceuticals (S) Pte Ltd (“CCM Singapore”) by CCM Duopharma Biotech Berhad from CCM International Sdn Bhd, a wholly-owned subsidiary of CCMB (“CCM International”), for a purchase consideration of RM2,417,000 together with the settlement of advances due from CCM Singapore to the CCMB Group amounting to RM27,000 based on 30 September 2014 to be settled via cash (“Singapore Company SSA”);
- (iv) A conditional share sale agreement dated 27 November 2014 for the proposed acquisition of the entire equity interest in CCM Pharma Sdn Bhd (“CCM Pharma”) and Upha Pharmaceutical Manufacturing (M) Sdn Bhd (“Upha Pharmaceutical”) by CCM Duopharma Biotech Berhad’s wholly-owned subsidiary, Duopharma (M) Sdn Bhd from CCMB, for an aggregate purchase consideration of RM113,307,000 together with the settlement of advances due from CCM Pharma and Upha Pharmaceutical to the CCMB Group amounting to RM101,116,000 based on 30 September 2014 to be settled via cash (“DMSB SSA”);

- (v) A supplementary share sale agreement dated 24 December 2014 by CCM Duopharma Biotech Berhad with CCMB (“Supplementary CCMD SSA”); and
- (vi) A supplementary share sale agreement dated 24 December 2014 by Duopharma (M) Sdn Bhd with CCMB (“Supplementary DMSB SSA”).
- (vii) A supplementary letter entered into between the Company and CCM Investments on 25 May 2015 in relation to the Philippines Company SSA dated 27 November 2014.
- (viii) An underwriting agreement entered into between the Company and RHB Investment Bank Berhad to underwrite 37,146,608 Rights Shares representing approximately 26.63% of the total Rights Shares, for which no undertaking has been obtained from shareholders of the Company, in relation to the Rights Issue Exercise
- (ix) A Facility Agreement for Commodity Murabahah Term Financing of up to RM245,123,000.00 (“Facility”) entered into between the Company and RHB Islamic Bank Berhad (“Bank”) on 26 June 2015.